article thumbnail

FDA approves Izervay for geographic atrophy

Drug Discovery World

The new complement C5 inhibitor is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase III clinical trials. The FDA approval of Izervay is great news for the retina community and our patients suffering from GA.”

article thumbnail

FDA approves first T cell therapy in solid tumours

Drug Discovery World

“The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a novel T cell immunotherapy for patients with limited treatment options.” Amtagvi is the first FDA-approved tumour-derived T cell immunotherapy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves first gene therapy for Duchenne muscular dystrophy

Drug Discovery World

“If EMBARK confirms the benefits seen in our prior trials, Sarepta will move rapidly to submit a BLA supplement to expand the approved label as broadly as good science permits.” The post FDA approves first gene therapy for Duchenne muscular dystrophy appeared first on Drug Discovery World (DDW).

article thumbnail

FDA approval represents ‘transformational progress’ in hypertension

Drug Discovery World

I am convinced that with the data we have seen, the approval of Tryvio heralds a new era of endothelin research beyond hypertension, where we intend to investigate the utility of aprocitentan for first-in-class applications in new indications.”

article thumbnail

FDA approves second indication for Lilly’s BTK inhibitor Jaypirca

Drug Discovery World

Jaypirca is the first FDA-approved non-covalent (reversible) BTK inhibitor. ” The post FDA approves second indication for Lilly’s BTK inhibitor Jaypirca appeared first on Drug Discovery World (DDW).

article thumbnail

FDA approves dual action tablet for BRCA-positive prostate cancer

Drug Discovery World

Janssen’s Akeega (niraparib and abiraterone acetate) is now available in the US for adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) following FDA approval. Approximately 10-15% of patients with mCRPC have BRCA gene alterations. With median follow-up at 24.8

article thumbnail

FDA-approved bladder cancer therapy reduces risk of death by 50%

Drug Discovery World

Ahsan Arozullah, Senior Vice President, Head of Oncology Development, Astellas, commented: “Today’s FDA approval represents a paradigm change in the treatment of advanced bladder cancer. ” The post FDA-approved bladder cancer therapy reduces risk of death by 50% appeared first on Drug Discovery World (DDW).